| Literature DB >> 27635417 |
Abstract
Natural killer cells are a diverse group of innate lymphocytes that are specialized to rapidly respond to cancerous or virus-infected cells. NK cell function is controlled by the integration of signals from activating and inhibitory receptors expressed at the cell surface. Variegated expression patterns of these activating and inhibitory receptors at the single cell level leads to a highly diverse NK cell repertoire. Here I review the factors that influence NK cell repertoire diversity and its functional consequences for our ability to fight viruses.Entities:
Keywords: NK cell or natural killer cell; diversity; lymphocyte; mass cytometry; repertoire; virus
Year: 2016 PMID: 27635417 PMCID: PMC5021221 DOI: 10.20411/pai.v1i1.142
Source DB: PubMed Journal: Pathog Immun ISSN: 2469-2964
NK cell receptor virus interactions
| Virus | NK Cell Receptor | Brief Description | Reference |
|---|---|---|---|
| CMV | NKG2C | NGK2C+ cells expand during CMV infection | [ |
| CMV | LIL-11, LIR-1 | UL18 inhibits LIR-11;activates LIR-1 | [ |
| CMV | NKp30 | NKp30 inhibited by pp65 | [ |
| CMV | NKG2D | Several viral proteins bind NKG2D to limit recognition | [ |
| Influenza | 2B4 and NTB-A | 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. | [ |
| Influenza | KIR2DL3 | KIR2DL3 and KIR3DL1 and HLA-C1 homozygosity leads to have enhanced IFN-γ secretion and degranulation to influenza A infection in vitro. Individuals with KIR3DL1/S1 or KIR2DL1 but lacking the ligand enriched among ICU patients during the 2009 flu pandemic, as were individuals with KIR2DL2/L3 and its cognate ligand. | [ |
| KIR2DL1 | |||
| KIR3DL1/S1 | |||
| Influenza | NKp46 | NKp46 interaction with HA leads to infected-cell lysis, with potential for escape of this pathway by NA-mediated removal of sialic acid residues from NKp46 to decrease recognition | [ |
| Influenza | NKG2D | NKG2D (and NKp46) mediated recognition of influenza-infect-ed dendritic cells | [ |
| HIV | CD94/HLA-E | CD94/HLA-E interaction may contribute to NK cell dysfunction in HIV infection | [ |
| HIV | FcRγ | FcRγ-NKp30-NKp46- NK cells are expanded in HIV and have enhanced ADCC activity | [ |
| HIV | KIR2DS4 | Full-length KIR2DS4 associated with disease progression | [ |
| HIV | KIR3DS1/KIR3DL1 | Combinations of KIR3DS1 and/or KIR3DL1 and HLA-Bw4-80I are associated with delayed HIV progression. KIR3DL1 and HLA-B density and binding alter education and HIV responsiveness; KIR3DS1+ NK cells expand and can kill HIV-infected cells | [ |
| HIV | KIR2DL1-3+ | KIR2DL1-imprinting on HIV strains; KIR2DL1-3+ NK cells more responsive | [ |
| HIV | KIR2DL3 | NKG2A+KIR2DL3+ cells potently secrete CC-chemokines, particularly in HLA-C2 individuals and KIR2DL3 is associated with resistance to HIV acquisition in HIV-exposed babies; selection of p24 sequence associated with KIR2DL3 escape | [ |
| HIV | LILRB1 | LILRB1+ NK cells control HIV-1 replication in DCs | [ |
| HIV | NCRs | NCRs are decreased in chronic HIV infection | [ |
| HIV | KIR | Nef induces endocytosis of HLA-I molecules, helping virus escape from NK cells | [ |
| HIV | NKG2D | Nef downregulated NKG2D ligand in infected cells causing decreased cytotoxicity | [ |
| HIV | NTB-A, UL-16BP | vpu/nef downregulate NK cell ligands: NTB-A, UL16-BP | [ |
| HIV | NKG2A | NKG2A+ NK cells respond more frequently than NKG2A- to HIV+ T cells; based on a conserved HIV-1-dervired peptide presented by HLA-E that renders cells susceptible to NKG2A | [ |
| HIV | NKG2D | NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. | [ |
| HIV | NKG2D/NKp46 | Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. | [ |
| HIV | NKp46 NKp30 | NKp30 and NKp46 expression correlates with AIDS-status of successfully treated patients | [ |
| HIV | NTB-A | Vpu downregulates NTB-A in infected T-cells, causing decreased degranulation by NK cells | [ |
| HIV | Siglec-7 | Siglec-7 is decreased in NK cells of viremic patients | [ |
| HIV and other pathogens | DNAM-1 and NKG2D | Review on NK-T crosstalk mediated by DNAM-1 and NKG2D and their ligands, in the context of infections | [ |
| HIV/HCV and other pathogens | NCRs | Reviews on NCRs and pathogen interactions | [ |
| HCV | KIR2DL2/L3 | KIR2DL3/L3 increases function; KIR2DL3/HLA1C1 is associated with response. | [ |
| HSV-2 | NKG2C, KIR, CD57 | HSV-2 infection drives NKG2A-NKG2C+KIR+CD57+ NK cells | [ |
| HSV, VSV | NKG2D | HSV decreases MICA, ULBP1, ULBP2, ULBP3 | [ |
| KSHV | LFA, others | K3 and K5 viral proteins downregulate MHC class I molecules, ICAM-1 ad B7-2, ligands for NK cell-mediated cytotoxicity receptors | [ |
| Hantavirus | NKG2C | NK cells expressing NKG2C expand (though most subjects also CMV+) | [ |
| Multiple viruses | NKG2D and NCR | Review summarizing data from multiple viruses mwith methods to decrease NKG2D and possible NCR ligands | [ |
| CHIKV | NKG2C and CD57 | Mature cells more responsive | [ |
| Dengue | Inhibitory KIRS | NK cells with inhibitor KIRs respond preferentially to DENV | [ |
| WNV and Dengue | NKp44 | NKp44 directly binds to purified DV and WNV envelope proteins. Interaction of NK cells with infective and inactivated WNV results in NKp44-mediated NK degranulation | [ |
Figure 1.Proposed model of the relationship between NK cell diversity and viral exposure. Based on the association between age, immune experience, and NK cell diversity, I propose that the NK cell repertoire begins as a naïve, flexible repertoire that is relatively homogenous from a phenotypic perspective, though it has extensive diversity in KIR expression patterns based on genetics. Upon encounter with different viruses, the NK cell repertoire diversifies, in part by increasing expression levels of activating receptors, as it seeks to adapt to the viral encounter. Each subsequent encounter further diversifies and specializes the repertoire. This specialization might contribute to memory/recall responses, but may also have the surprising effect of diminishing the ability to respond to de novo pathogens. Vaccine and viral challenge studies in human and animal models will be needed to validate or invalidate this model.